Selective estrogen receptor degraders in premenopausal breast cancer: Biological activity and endpoint relevance in window of opportunity trials.

Authors

Ana-Maria Dudău, Jean Zeghondy, George Emile, Camille Simon, Marine Lottin, Antonio Marra, Philippe Aftimos, Stergios Boussios, Alexandre Xu-Vuillard, Ophélie Lion, Chloe Serhal, Joana M Ribeiro, Barbara Pistilli, Stefan Michiels, Elie Rassy

Published in

Cancer treatment reviews. Volume 150. Pages 103213. Sep 13, 2026. Epub Sep 13, 2026.

Abstract

Selective estrogen receptor degraders (SERDs) have emerged as a key therapeutic class in hormone receptor-positive (HR+) breast cancer, combining estrogen receptor (ER) antagonism with direct receptor degradation. Despite this dual mechanism, pivotal trials of SERDs in premenopausal patients-across both metastatic and adjuvant settings-have mandated concurrent ovarian function suppression (OFS). Mechanistically, because ER undergoes continuous synthesis, both receptor antagonism and degradation require sustained occupancy of the ligand-binding domain. The central question is therefore one of competitive target engagement-whether oral SERDs can achieve and maintain adequate receptor occupancy in a high-estrogen premenopausal environment, independent of their intrinsic degradation efficiency. Reframing the debate around this competitive binding dynamic, rather than degradation capacity alone, offers a more mechanistically complete basis for evaluating OFS necessity in premenopausal patients. Window-of-opportunity (WOO) trials have offered an early opportunity to probe this question, consistently demonstrating rapid ER downregulation and antiproliferative activity with SERD monotherapy. Yet interpretation of these findings is complicated by substantial heterogeneity across trials in patient selection, comparator design, treatment duration, tissue sampling strategy, and endpoint definition. Moreover, the endpoints most used to gauge pharmacodynamic response-Ki67 suppression and complete cell cycle arrest (CCCA)-were validated in postmenopausal populations treated with aromatase inhibitors or tamoxifen, agents that act primarily through estrogen deprivation or competitive antagonism rather than receptor degradation. Their applicability to SERDs, and to the distinct estrogen milieu of premenopausal patients, remains under investigation. This narrative review critically summarizes the development of oral SERDs in metastatic HR+ breast cancer, review findings from window-of-opportunity trials, discuss emerging evidence in premenopausal women and addresses the methodological variability, underlying biological considerations, and limitations of conventional pharmacodynamic endpoints.

PMID:
42748873
Bibliographic data and abstract were imported from PubMed on 17 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.